The Top 10 World's Leading Pharmaceutical Companies

Publication Date	January 2008
Publisher	Venture Planning Grp.
Product Type	Report
Pages	1300
ISBN Number
Product Code	VEP00130

Price

£7,065.00
approximately: $13,201 | €8,961

PDF

PRINT £5,885 ($10,996 | €7,464)

Order above formats by FAX

Summary

In a highly dynamic and fragmented pharmaceutical market, besieged by intense competition, rapid pace of technological innovations and the uncertainty regarding future government regulations, the ability to anticipate new competitive product introductions and marketing strategies is particularly important... and spells the difference between success and failure. The TOP 10, a unique series of market intelligence studies first introduced by VENTURE PLANNING GROUP in 1987, is designed to provide the pharmaceutical industry executives, as well as companies planning to diversify into the pharmaceutical field, with strategically significant competitor information, analysis and insight, critical to the development and implementation of effective marketing and R&D programs. The study's major objectives include: to establish a comprehensive, factual, annually-updated and cost-effective; information base on performance, capabilities, goals and strategies of the world's leading pharmaceutical companies; to help current suppliers realistically assess their financial, marketing and technological capabilities vis--vis leading competitors; to assist potential market entrants in evaluating prospective acquisitions and joint venture candidates; and to complement organizations' internal competitor information gathering efforts by providing strategic analysis, data interpretation and insight. The study provides an approximately 50-page worldwide strategic overview of the pharmaceutical market, including sales forecast for major product segments (ethical, OTC, generics); key geographic regions (North America, Western Europe, Japan, Eastern Europe, and Latin America); major drug categories, including cardiovascular, gastrointestinal, antibiotics, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, and others. In addition, the report reviews major U.S. and international regulatory, technological, economic, demographic, and social trends with potentially significant impact on the pharmaceutical industry during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. For each of the TOP 10 companies, the report provides: Executive Summary; Business Organization; Senior Management; Facilities and Employees; Technological Know-How; Product Portfolio Analysis; Marketing Tactics; Financial Analysis; R&D Expenditures and Major Programs; Collaborative Arrangements; and Strategic Direction.

Content

Section I: Executive Summary
- A 5-10 Page Synopsis of Key Sections.
Section Ii: Business Organization
- History of The Company's Pharmaceutical Business Evolution, Which Is Important to Understanding The Corporate Culture, Management Mentality, and Strategies.
- Most Recent M&A Activity and Significant Organizational Changes.
- Current Organizational Structure.
Section Iii: Senior Management
- Names, Titles, and Background of Senior Managers.
Section Iv: Facilities and Employees
- Major Administrative, Manufacturing, and R&D Facilities in The U S. and Abroad.
- Manufacturing Practices.
- New Plants under Construction.
- U S. and International Work Force Size and Distribution.
Section V:Technological Know-How
- Internally Developed and Acquired Technologies, Processes, and Related Capabilities.
- Know-How in Biotechnology and Other Pertinent Fields.
- Proprietary Technologies and Patent Litigations.
Section Vi: Product Portfolio Analysis
- Extensive Review of Major Ethical, Otc, and Generic Drugs.
- Most Recent New Drug Introductions and Indications.
Section Vii: Marketing Tactics
- Sales Force Size and Structure in The U S , Europe, Japan, and Other Regions.
- Major Sales Office Locations.
Section Vii: Marketing Tactics
- Sales Force in The U S , Europe, and Other Regions.
- Distribution Strategies.
- Major Promotional Tactics.
Section Viii: Financial Analysis
- The 2006 U S. and International Sales and Operating Profit Estimates by Division, Geographic Region, Therapeutic Category, and Individual Drug.
- The 2002-2006 Sales and Operating Profit Performance.
Section Ix: R&D Expenditures and Major Programs
- The 2006 R&D Budget.
- Research Facilities and Staff.
- New Technologies, Drugs, and Indications in Development, Including Their Phase and Anticipated Introduction Dates.
- Worldwide Sales Force Size.
Section X: Collaborative Arrangements
- Major Joint Venture, Distribution, OEM, and Licensing Partners, Both Industrial and Academic.
- Terms of Collaborative Agreements and Specific Products Involved.
Section Xi: Strategic Direction
- Major Strengths and Weaknesses.
- Business, New Product Development, and Marketing Objectives and Strategies.
- Anticipated Acquisitions, Joint Ventures, and Divestitures.